BioVision 06/16 For research use only

Anti-CD4 (), Human IgG4

CATALOG NO: A1091-200 REFERENCE: Newman et al. Primatization of recombinant for of human diseases: a macaque/human chimeric antibody against ALTERNATIVE NAMES: p55; surface T4/Leu-3 human CD4. Biotechnology (NY). 1992 Nov; 10 (11):1455-60.

AMOUNT: 200 µg

IMMUNOGEN: Domain 1 of human CD4 RELATED PRODUCTS:

ISOTYPE / FORMAT: Human IgG4, lambda  Anti-VEGF (Bevacizumab), (Cat. No. A1045-100)

CLONALITY: Monoclonal  Anti-HER2 (Trastuzumab), humanized Antibody (Cat. No. A1046-100)

 Anti-EGFR (Cetuximab), Chimeric Antibody (Cat. No. A1047-100) CLONE: CE9.1  Anti-TNF-α (), humanized Antibody (Cat. No. A1048-100) SPECIES REACTIVITY: Human, chimpanzee  Anti-CD20 (), Chimeric Antibody (Cat. No. A1049-100) FORM: Liquid  Anti-EGFR (Panitumumab), humanized antibody (Cat. No. A1050-100)

SPECIFICITY: The antibody binds to human CD4 with a Kd of 1.0 nM and an  Anti-OX40L (), Human IgG1 Antibody (Cat. No. A1088-200) ED50 of 0.2 ug/ml.  Anti-CD11a (), Human IgG1 Antibody (Cat. No. A1089-200)

PURIFICATION: Affinity purified using Protein A  Anti-EGFR (Matuzumab), Human IgG1 Antibody (Cat. No. A1090-200)

 Anti-alpha 5 beta1 (Volociximab), Human IgG4 Antibody (Cat. No. A1092- FORMULATION: Supplied in PBS with preservative (0.02% Proclin 300) 200) ° STORAGE CONDITIONS: Store at 4 C for upto 3 months. For long term storage, aliquot and  Anti-TNF alpha (Humicade), Human IgG4 Antibody (Cat. No. A1093-200) freeze at -20°C. Avoid repeated freeze/defrost cycles.  Anti-CD40L (), Human IgG1 Antibody (Cat. No. A1094-200) DESCRIPTION: Recombinant to CD4. Manufactured using  Anti-Human Ephrin Type A receptor 2 (1C1), Human IgG1 Antibody (Cat. No. A1095- recombinant technology with variable regions (i.e. specificity) from 200) the hybridoma CE9.1 (Clenoliximab). This reformatted human antibody was made using the variable domain sequences of the  Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Antibody (Cat. No. original Human IgG4 (primatized) format, for improved compatibility A1096-200) with existing reagents, assays and techniques.  Anti-TNF alpha (), Human IgG1 Antibody (Cat. No. A1097-200) BACKGROUND: The antibody binds specifically to CD4, a molecule which is part of  Anti-IL-2R alpha (CD25) (), Human IgG1 Antibody (Cat. No. A1098-200) the immunolgobulin super-family, expressed on the surface of helper T cells. The CD4 molecule acts as a co-receptor in the  Anti-IL-2R alpha (), Human IgG1 Antibody (Cat. No. A1099-200) activation of T cells, aiding the interaction between the TCR and

MHC II of the antigen-presenting cell. The antibody is classified as "primatized", as the variable regions of the light and heavy chains are obtained from primates, while the lamda light chain and γ4 heavy chain constant domains are human. The antibody was engineered from the primatized IgG1 monoclonal antibody by substituting two key residues. The role of the antibody as an immunosuppressor has been tested in vivo, by intravenous administration in chimpanzees and human volunteers. The antibody reached Phase II clinical trials with Biogen-Idec. FOR RESEARCH USE ONLY! Not to be used on humans. APPLICATION: ELISA; FC; Block; SPR; IHC

BioVision Incorporated Tel: 408-493-1800 | Fax: 408-493-1801

155 S. Milpitas Boulevard, Milpitas, CA 95035 USA www.biovision.com | [email protected]